Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 15

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 15
---
, the Company is exploring the potential utility of Tafenoquine
    to manage equine Theileria (a tick-borne disease related to babesiosis). Horses entering the United States are required to be tested
    prior to quarantine release and treated if positive.

Treatment
and Prevention of Fungal Infections

We
are evaluating Tafenoquine for potential utility in the following fungal diseases:

    ●
    Treatment
    of Candida infections. According to the CDC, there are 50,000 reported cases of candidiasis (a type of fungal infection)
    each year in the United States and up to 1,900 clinical cases of C. auris, for which there are few available treatments.14
    Since it has broad-spectrum activity against drug-resistant Candida spp in culture, Tafenoquine, has the potential to
    be a market leading therapy for treatment/prevention of C. auris, and to be added to the standard of care regimens for other
    Candida infections.15

    ●
    Prevention
    of fungal pneumonias. There are up to ~ 91-92,000 new patient cases each year in the United States for which antifungal prophylaxis
    is recommended, including acute lymphoblastic leukemia (up to 6,540 cases) and large B-cell lymphoma (up to 18,000 cases) patients
    receiving CAR-T therapy, solid organ transplant patients (up to 42,887 cases), allogeneic (~ 9,000 cases) and autologous (~ 15,000
    cases) hematopoietic stem cell transplant patients.16 Despite the availability and use of antifungal prophylaxis, the
    risk of some patient groups contracting fungal pneumonia exceeds the risk of contracting malaria during travel to West Africa.17
    Since it has broad spectrum antifungal effects in cell culture, and activity against Pneumocystis in animal models,
    Tafenoquine has the potential to be added to existing standard of care regimens for the prevention of fungal pneumonias.18

Viral
Diseases

Celgosivir, a potential clinical candidate of
60P’s, has activity in a number of animal models of important viral diseases such as Dengue and RSV. According to the European
CDC, Dengue is associated with at least 4.1 million cases globally.19 And, according to the U.S.